Physician profile
Michael D Gerlach
NPI 1962476093
$9,190.21
in general payments reported to CMS, 2019-2025
42 companies · $982 in 2025
The $982 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,526 · 2020: $763 · 2021: $1,677 · 2022: $1,398 · 2023: $1,285 · 2024: $1,559 · 2025: $982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,781 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,781.07 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,349.14 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,342.58 | 2019-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $969.02 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $953.35 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $664.97 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $612.74 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $406.51 | 2019-2025 | Vaxelis, Gardasil 9, Capvaxive |
| Novo Nordisk INC | $400.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Grifols USA, LLC | $269.52 | 2020-2024 | Prolastin-C Liquid |
| Astellas Pharma US INC | $257.35 | 2019-2024 | Veozah |
| Abbvie INC. | $172.20 | 2021-2025 | |
| Amarin Pharma, INC. | $168.55 | 2020-2022 | |
| Abbott Laboratories | $164.53 | 2021-2025 | Freestyle Libre 3 |
| Sunovion Pharmaceuticals INC. | $162.29 | 2019 | |
| Phathom Pharmaceuticals, INC. | $148.88 | 2024-2025 | Voquezna |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gerlach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.